Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

Hepatology

Volumn 54, Issue 4, 2011, Pages 1118-1120

  Rinella, Mary E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE;

CANCER RISK; CARDIOVASCULAR DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; ETHNICITY; FATALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; TREATMENT INDICATION; UNITED STATES; VIRAL CLEARANCE; WEIGHT REDUCTION;

FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE;

EID: 80053319811     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24634     Document Type: Editorial

References (16)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. HEPATOLOGY 2011;54:1208-1216.
3. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011; 34: 210-215.
4. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. HEPATOLOGY 2003; 38: 420-427.
5. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
6. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804.
7. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
8. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. HEPATOLOGY 2011; 53: 1883-1894.
9. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A 2004; 101: 11269-11274.
10. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; for NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
11. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
12. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001; 96: 2462-2467.
13. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. HEPATOLOGY 2002; 36: 1206-1213.
14. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al.; for HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. HEPATOLOGY 2011; 54: 396-405.
15. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2010; 51: 1972-1978.
16. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.